Skip to main content
. 2016 Nov 18;6(1):e1261240. doi: 10.1080/2162402X.2016.1261240

Figure 4.

Figure 4.

MV induces IFN-α and TRAIL expression following RLR activation in CD1c+ DCs and RLR/TLR7 activation in pDCs. (A) pDCs were pretreated or not with IRS661 (TLR7 inhibitor) or with MRT67307 (TBK1 and IKK-ε inhibitor) and then cultured with IL3, IL3+MV or R837. (B) CD1c+ DCs were pretreated or not with IRS661 or MRT67307 and then cultured alone (−) or with MV. (C) pDCs were cultured with IL3+MV or with IL3+UV-inactivated MV (MV UV*) and CD1c+ DCs were cultured alone (−), with MV or MV UV*. (D) pDCs and CD1c+ DCs were exposed to 5′-ppp-dsRNA LyoVec, a RIG-I agonist. (A–D) IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). The expression of TRAIL by the indicated cells was determined by flow cytometry. Results are expressed as the mean ± SEM of three independent experiments. (A, B) *p < 0.05, one-way ANOVA (Kruskal–Wallis). (C) *p < 0.05, Mann–Whitney test.